New diabetes device data puts Merck's Januvia on notice

Merck's ($MRK) Januvia has seen its fair share of competition from generics makers and other diabetes challengers. But now, it could face a new rival on the scene--and it's a device. Boston-based Intarcia is touting data showing its tiny, implantable drug pump beat out Merck's best-seller in a head-to-head trial, reducing a type of hemoglobin linked to diabetes twice as much as Januvia. Story

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.